This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | MicrobiomeTrials
← Back to trials NCT07221474
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-12-12Est. Completion: 2029-07-02
Enrollment target: 180 participantsLocations Moffitt Cancer Center ( Site 0021), Tampa, Florida, United States Washington University School of Medicine ( Site 0024), St Louis, Missouri, United States Valley Health Systems - Ridgewood Campus ( Site 0010), Paramus, New Jersey, United States Cleveland Clinic - Ohio ( Site 0016), Cleveland, Ohio, United States Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000), Nashville, Tennessee, United States Texas Oncology - Central/South Texas ( Site 8002), Austin, Texas, United States Virginia Cancer Specialists ( Site 0003), Fairfax, Virginia, United States Hospital Italiano de Buenos Aires ( Site 0200), Ciudad Autonoma de Buenos Aires., Buenos Aires, Argentina Instituto Alexander Fleming ( Site 0201), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina Instituto de Investigaciones Clínicas Mar del Plata ( Site 0205), Mar del Plata, Buenos Aires, Argentina Clinica Adventista Belgrano ( Site 0206), Caba., Buenos Aires F.D., Argentina Fundacion Estudios Clinicos ( Site 0207), Rosario, Santa Fe Province, Argentina Sanatorio Parque ( Site 0203), Rosario, Santa Fe Province, Argentina Other microbiome trials you might be interested in Metastatic Non-Squamous Non-Small Cell Lung Cancer Adult Solid Tumor
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti…
Birmingham, United States Est. completion Oct 1, 2029
Advanced Esophageal Squamous Cell Carcinoma Advanced Renal Cell Carcinoma Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 Clinical Stage IIB Cutaneous Melanoma AJCC v8
Westmead Hospital ( Site 0400), Westmead, New South Wales, Australia
Princess Alexandra Hospital ( Site 0403), Woolloongabba, Queensland, Australia
One Clinical Research ( Site 0402), Nedlands, Western Australia, Australia
Centro de Estudios Clínicos SAGA ( Site 0307), Santiago, Region M. de Santiago, Chile
FALP ( Site 0300), Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0301), Santiago, Region M. de Santiago, Chile
Bradford Hill Norte ( Site 0308), Antofagasta, Chile
Centre Georges François Leclerc ( Site 0805), Dijon, Cote-d Or, France
Institut de Cancérologie de l'Ouest ( Site 0801), Angers, Pays de la Loire Region, France
CHU GABRIEL MONTPIED ( Site 0802), Clermont-Ferrand, Puy-de-Dome, France
Ospedale Santa Maria delle Croci-Dipartimento Oncoematologico ( Site 1004), Ravenna, Emilia-Romagna, Italy
Ospedale San Raffaele-Oncologia Medica ( Site 1002), Milan, Italy
Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 1000), Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1001), Roma, Italy
Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1101), Poznan, Greater Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 1100), Warsaw, Masovian Voivodeship, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1102), Przemyśl, Podkarpackie Voivodeship, Poland
National Cancer Center ( Site 0504), Goyang-si, Kyonggi-do, South Korea
Seoul National University Bundang Hospital ( Site 0500), Seongnam-si, Kyonggi-do, South Korea
Chungbuk National University Hospital-Internal medicine ( Site 0501), Cheongju-si, North Chungcheong, South Korea
Asan Medical Center ( Site 0503), Seoul, South Korea
Samsung Medical Center ( Site 0502), Seoul, South Korea
ICO L Hospitalet ( Site 1311), Hospitalet, Barcelona, Spain
Hospital Jerez de la Frontera-UGC Oncología ( Site 1315), Jerez de la Frontera, Cadiz, Spain
Hospital Universitari Vall d''Hebron ( Site 1310), Barcelona, Spain
Hospital Ramon y Cajal ( Site 1314), Madrid, Spain
Hospital Clinico San Carlos... ( Site 1313), Madrid, Spain
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1312), Seville, Spain
China Medical University Hospital ( Site 0606), Taichung, Taiwan
National Cheng Kung University Hospital ( Site 0601), Tainan, Taiwan
Mackay Memorial Hospital ( Site 0604), Taipei, Taiwan
National Taiwan University Cancer Center (NTUCC) ( Site 0600), Taipei, Taiwan
Taipei Veterans General Hospital ( Site 0602), Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 0605), Taoyuan, Taiwan
Hacettepe Universitesi Tıp Fakultesi ( Site 1400), Ankara, Turkey (Türkiye)
Memorial Ankara Hastanesi ( Site 1401), Ankara, Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi ( Site 1402), Ankara, Turkey (Türkiye)
Koç Üniversitesi Hastanesi ( Site 1403), Istanbul, Turkey (Türkiye) Clinical Stage IIC Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
Esophageal Carcinoma
Gastroesophageal Junction Adenocarcinoma
Hepatocellular Carcinoma
Locally Advanced Urothelial Carcinoma
Lung Non-Small Cell Carcinoma
Malignant Solid Neoplasm
Metastatic Colorectal Carcinoma
Metastatic Cutaneous Melanoma
Metastatic Esophageal Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Esophageal Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage IV Renal Cell Cancer AJCC v8
Unresectable Cutaneous Melanoma
Unresectable Esophageal Squamous Cell Carcinoma
Urothelial Carcinoma
Unresectable Urothelial Carcinoma
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setti…
Jacksonville, United States Est. completion Dec 31, 2026
Recurrent Squamous Cell Lung Carcinoma Stage IV Squamous Cell Lung Carcinoma AJCC v7
This randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in treating patients with stage I…
Birmingham, United States Est. completion Dec 19, 2019